GE Healthcare to Provide Cytori’s Adipose-Derived Stem Cell Technology in North America
GE Healthcare agreed to commercialize Cytori Therapeutics’ StemSource® technology in the North American stem cell banking and research markets. The partnership will extend for 18 months starting in the second quarter of 2009.
StemSource includes automated equipment to process stem and regenerative cells found in adipose tissue, cryopreserve them, or use them directly for research purposes.
In January 2009, Cytori and GE Healthcare formed a separate agreement to commercialize Cytori’s products in 10 European countries. This includes selling the Celution® 800/CRS System in the European cosmetic and reconstructive surgery market as well as selling
StemSource products in the European cell banking and research markets.